<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368277</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2344</org_study_id>
    <nct_id>NCT00368277</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly</brief_title>
  <official_title>A 36 Week Randomized, Double-blind, Parallel Group, Multi-center, Active-controlled, Optional Titration Study Comparing an Aliskiren-based Regimen to a Ramipril-based Regimen in Patients ≥ 65 Years Old With Systolic Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to
      ramipril 5mg and 10mg in elderly patients with essential systolic hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Cough</measure>
    <time_frame>Weeks 12 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Blood Pressure Control at Weeks 12 and 36 Endpoints</measure>
    <time_frame>Weeks 12 and 36</time_frame>
    <description>Blood pressure control is defined as a mean sitting blood pressure &lt; 140/90 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Sitting Diastolic Blood Pressure to Week 36</measure>
    <time_frame>Baseline and week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">901</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Aliskiren-based regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramipril-based regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning</description>
    <arm_group_label>Aliskiren-based regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning</description>
    <arm_group_label>Ramipril-based regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning</description>
    <arm_group_label>Aliskiren-based regimen</arm_group_label>
    <arm_group_label>Ramipril-based regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning</description>
    <arm_group_label>Aliskiren-based regimen</arm_group_label>
    <arm_group_label>Ramipril-based regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients ≥ 65 years old.

          -  Patients with essential hypertension with an msSBP ≥ 140 mmHg and &lt; 180 mmHg, and
             msDBP &lt; 110 mmHg at Visits 2 and 3. (Visit 201 was deleted by the Administrative
             Changes document.)

          -  Patients must have had a difference in msSBP of ≤ 20 mmHg between Visit 3 and the
             visit immediately prior to Visit 3.

          -  Patients who were eligible and able to participate in the study, and who consented to
             do so after the purpose and nature of the investigation had been explained to them
             (written informed consent).

        Exclusion Criteria:

          -  History of renal artery stenosis.

          -  Known Keith-Wagener grade III or IV hypertensive retinopathy.

          -  History of hypertensive encephalopathy.

          -  Current diagnosis of heart failure (New York Heart Association Class III-IV).

          -  History of transient ischemic cerebral attack or cerebrovascular accident within 6
             months.

          -  History of myocardial infarction, bypass surgery, or any percutaneous coronary
             intervention within 6 months.

          -  Current unstable angina pectoris. Patients on a stable dose of oral or topical
             nitrates or beta blockers for angina were acceptable.

          -  Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.

          -  Clinically significant valvular heart disease.

          -  Concurrent use of any antihypersensitive medications except a stable dose 3 months
             prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy (e.g.,
             Flomax for BPH), beta blockers for angina, or beta blockers ophthalmic preparations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2006</study_first_submitted>
  <study_first_submitted_qc>August 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2006</study_first_posted>
  <results_first_submitted>December 14, 2010</results_first_submitted>
  <results_first_submitted_qc>February 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 25, 2011</results_first_posted>
  <last_update_submitted>February 28, 2011</last_update_submitted>
  <last_update_submitted_qc>February 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Systolic hypertension</keyword>
  <keyword>hypertension</keyword>
  <keyword>aliskiren</keyword>
  <keyword>blood pressure</keyword>
  <keyword>ramipril</keyword>
  <keyword>HTN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren Based Treatment Regimen</title>
          <description>Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg</description>
        </group>
        <group group_id="P2">
          <title>Ramipril Based Treatment Regimen</title>
          <description>Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="457"/>
                <participants group_id="P2" count="444"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="344"/>
                <participants group_id="P2" count="336"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="108"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren Based Treatment Regimen</title>
          <description>Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg</description>
        </group>
        <group group_id="B2">
          <title>Ramipril Based Treatment Regimen</title>
          <description>Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="457"/>
            <count group_id="B2" value="444"/>
            <count group_id="B3" value="901"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.0" spread="5.56"/>
                    <measurement group_id="B2" value="72.2" spread="5.62"/>
                    <measurement group_id="B3" value="72.1" spread="5.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>65 - 74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="312"/>
                    <measurement group_id="B2" value="296"/>
                    <measurement group_id="B3" value="608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 years and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="237"/>
                    <measurement group_id="B3" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="222"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure to Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent to treat (ITT), Last Observation Carried forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren Based Treatment Regimen</title>
            <description>Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Based Treatment Regimen</title>
            <description>Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure to Week 12</title>
          <population>Intent to treat (ITT), Last Observation Carried forward (LOCF)</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="439"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.96" spread="0.754" lower_limit="-15.15" upper_limit="-12.13"/>
                    <measurement group_id="O2" value="-11.64" spread="0.759" lower_limit="-12.76" upper_limit="-9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Cough</title>
        <time_frame>Weeks 12 and 36</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren Based Treatment Regimen</title>
            <description>Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Based Treatment Regimen</title>
            <description>Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Cough</title>
          <population>Safety population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
                <count group_id="O2" value="444"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.788"/>
                    <measurement group_id="O2" value="9.9" spread="0.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Blood Pressure Control at Weeks 12 and 36 Endpoints</title>
        <description>Blood pressure control is defined as a mean sitting blood pressure &lt; 140/90 mm Hg</description>
        <time_frame>Weeks 12 and 36</time_frame>
        <population>intent to treat (ITT), last observation carried forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren Based Treatment Regimen</title>
            <description>Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Based Treatment Regimen</title>
            <description>Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Blood Pressure Control at Weeks 12 and 36 Endpoints</title>
          <description>Blood pressure control is defined as a mean sitting blood pressure &lt; 140/90 mm Hg</description>
          <population>intent to treat (ITT), last observation carried forward (LOCF)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="440"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 12 endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3"/>
                    <measurement group_id="O2" value="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 36 endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6"/>
                    <measurement group_id="O2" value="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Sitting Diastolic Blood Pressure to Week 36</title>
        <time_frame>Baseline and week 36</time_frame>
        <population>Intent to treat (ITT), Last Observation Carried forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren Based Treatment Regimen</title>
            <description>Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Ramipril Based Treatment Regimen</title>
            <description>Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Sitting Diastolic Blood Pressure to Week 36</title>
          <population>Intent to treat (ITT), Last Observation Carried forward (LOCF)</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="439"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.24" spread="0.409"/>
                    <measurement group_id="O2" value="-7.02" spread="0.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren</title>
          <description>Aliskiren based regimen</description>
        </group>
        <group group_id="E2">
          <title>Ramipril</title>
          <description>Ramipril based regimen</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Eye movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Aphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Myringitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Colon cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Head and neck cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="444"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="452"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="444"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novaris Phamaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

